AI Article Synopsis
Article Abstract
Overexpression of erbB2 is associated with resistance to apoptosis. We explored whether high level of erbB2 expression by cancer cells allows their targeting using an erbB2-binding peptide (LTVSPWY) attached to the proapoptotic alpha-tocopheryl succinate (alpha-TOS). Treating erbB2-low or erbB2-high cells with alpha-TOS induced similar levels of apoptosis, whereas alpha-TOS-LTVSPWY induced greater levels of apoptosis in erbB2-high cells. alpha-TOS rapidly accumulated in erbB2-high cells exposed to alpha-TOS-LTVSPWY. The extent of apoptosis induced in erbB2-high cells by alpha-TOS-LTVSPWY was suppressed by erbB2 RNA interference as well as by inhibition of either endocytotic or lysosomal function. alpha-TOS-LTVSPWY reduced erbB2-high breast carcinomas in FVB/N c-neu transgenic mice. We conclude that a conjugate of a peptide targeting alpha-TOS to erbB2-overexpressing cancer cells induces rapid apoptosis and efficiently suppresses erbB2-positive breast tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/0008-5472.CAN-06-2480 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigation of Tumor Heterogeneity Using Integrated Single-Cell RNA Sequence Analysis to Focus on Genes Related to Breast Cancer-, EMT-, CSC-, and Metastasis-Related Markers in Patients with HER2-Positive Breast Cancer.
Cells
September 2023
Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo 104-0045, Japan.
Article Synopsis
- The study focuses on the HER2 protein as a target for HER2-overexpressing breast cancer, noting the development of targeted HER2 strategies and the challenge of drug resistance due to intratumoral heterogeneity.
- An integrated analysis of single-cell gene expression data reveals a varied distribution of breast cancer-related gene expressions among HER2-positive cases, comparing these findings to luminal breast cancer datasets.
- Key differences in gene expression levels were found between high and low HER2 groups, as well as between ER-positive and ER-negative cases, indicating that molecular characteristics and diversity in gene expression can vary significantly among individual patients.
Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.
JAMA Oncol
March 2022
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, England.
Article Synopsis
- Rare germline genetic variants in specific genes are linked to increased breast cancer risk, but their impact on different subtypes of the disease is not fully understood.
- The BRIDGES study analyzed data from 42,680 breast cancer patients and 46,387 controls, focusing on specific genetic mutations and their associations with tumor characteristics.
- Results showed that certain gene variants (like RAD51C, RAD51D, and BARD1) are primarily linked to triple-negative breast cancer, while others (like CHEK2) are associated with various subtypes, indicating varied genetic influence on breast cancer types.
Comprehensive Analysis and Identification of Prognostic Biomarkers and Therapeutic Targets Among FAM83 Family Members for Gastric Cancer.
Front Cell Dev Biol
November 2021
Center of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Gastric cancer (GC) is one of the most common and poor prognosis malignancy in the world. The Family with sequence similarity 83 (FAM83) comprises of eight members of A-H. Accumulating evidence confirmed important roles for FAM83 family in tumorigenesis and progression.
View Article and Find Full Text PDFQuantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density.
ACS Nano
January 2020
Department of Biomedical Engineering , Duke University, Durham , North Carolina 27708 , United States.
Multivalent nanoparticles that target a cell surface receptor that is overexpressed by cancer cells are a promising delivery system for cancer therapy. However, the impact of the receptor density and nanoparticle ligand valency on the cell uptake has not been studied in a system where both variables can be systematically tuned over a wide range. To address this lacuna, we report cell-uptake studies on a genetically engineered breast cancer cell line with tunable ErbB2 expression by a polypeptide micelle with tunable ligand valency.
View Article and Find Full Text PDFImpact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
Ann Oncol
April 2018
Division of Hematology-Oncolog, Department of Medicine, Samsung Medical Center, Seoul, Korea; Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:
Background: To identify predictive markers for responders in lapatinib-treated patients and to demonstrate molecular changes during lapatinib treatment via cell-free genomics.
Patients And Methods: We prospectively evaluated the efficacy of combining lapatinib with capecitabine and oxaliplatin as first line neoadjuvant therapy in patients with previously untreated, HER2-overexpressing advanced gastric cancer. A parallel biomarker study was conducted by simultaneously performing immunohistochemistry and next-generation sequencing (NGS) with tumor and blood samples.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!